Sartorius, a leading international partner of life science research and biopharmaceutical industries, has acquired Visikol, a contract research services company, for an undisclosed amount. This strategic acquisition sees Sartorius expanding its capabilities in advanced drug discovery and development services. Visikol specializes in accelerating the drug discovery and development process through advanced tissue imaging and sophisticated cell culture services, counting all twenty of the top twenty pharmaceutical companies among its clientele.
Visikol’s comprehensive service portfolio includes end-to-end solutions such as 3D tissue imaging, multiplex tissue imaging, digital pathology, and high content imaging. Additionally, the company provides a range of 2D and 3D cell culture assays, including ex vivo tissue slice assays. Visikol's expertise is pivotal in transforming tissues into actionable insights and bridging the gap between in vitro assays and in vivo results using best-in-class cell culture models. Beyond services, Visikol also supplies a suite of tissue clearing reagents and kits, as well as the HUREL® Micro Liver portfolio of primary hepatocyte liver models.
The acquisition is strategically significant for Sartorius, enabling it to integrate Visikol’s specialized expertise and advanced technologies directly into its existing portfolio. This move is expected to create substantial synergies by broadening Sartorius's R&D service capabilities and enhancing its value proposition to pharmaceutical and biotech clients globally. Visikol’s advanced imaging and cell culture tools, instrumental in numerous drug discovery programs, will complement Sartorius's mission to support scientists and engineers. This corporate acquisition by Sartorius of Visikol's operations and assets is designed to secure new service offerings and market reach, distinctly separate from a funding round.
Looking ahead, the combined entity aims to deliver more comprehensive and integrated solutions for accelerating drug discovery and development. By bringing together Sartorius's extensive market presence with Visikol's innovative scientific services and products, the acquisition is anticipated to strengthen their collective impact on advancing biopharmaceutical research, offering clients enhanced tools and expertise to address complex scientific challenges.